Alpha Tau Medical Ltd. 是一家臨床階段的腫瘤治療公司,在以色列和美國從事用於治療實體癌的α發射放射治療(Alpha DaRT)的研究、開發和商業化。公司總部位於以色列耶路撒冷。
財務指標
營業收入
2026-06-30
$0
2026-03-31
$0
2025-12-31
$0
2025-09-30
$0
營業支出
2026-06-30
$13.78M
2026-03-31
$13.31M
2025-12-31
$12.6M
2025-09-30
$10.73M
淨利潤
2026-06-30
-$45.81M
2026-03-31
-$22.93M
2025-12-31
-$12.13M
2025-09-30
-$11.68M
淨利潤率
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
每股收益
2026-06-30
$-0.50
2026-03-31
$-0.26
2025-12-31
$-0.14
2025-09-30
$-0.14
息稅折舊攤銷前利潤
2026-06-30
-$13.78M
2026-03-31
-$13.31M
2025-12-31
-$11.24M
2025-09-30
-$10.73M
有效稅率
2026-06-30
-0.5%
2026-03-31
0.04%
2025-12-31
0.28%
2025-09-30
0.06%
項目
2026-06-30
2026-03-31
2025-12-31
2025-09-30
營業收入
$0
$0
$0
$0
營業支出
$13.78M
$13.31M
$12.6M
$10.73M
淨利潤
-$45.81M
-$22.93M
-$12.13M
-$11.68M
淨利潤率
--
--
--
--
每股收益
$-0.50
$-0.26
$-0.14
$-0.14
息稅折舊攤銷前利潤
-$13.78M
-$13.31M
-$11.24M
-$10.73M
有效稅率
-0.5%
0.04%
0.28%
0.06%
常見問題
DRTS represents the ticker for a publicly traded company whose specific business operations are detailed on its stock page. The company operates within its designated industry, and its core activities directly influence financial performance. To understand what DRTS does, review the company profile and recent filings available on the page. This information helps investors assess the company's business model, revenue sources, and competitive position.
Recent performance for DRTS can be tracked through the latest price data on the page, which shows changes over various periods. Stock performance reflects market sentiment, company news, and broader economic trends. For the most accurate and current figures, refer to the live quote and historical chart provided. This data helps investors understand short-term momentum without relying on outdated information.
Evaluating DRTS valuation involves reviewing metrics such as price-to-earnings, price-to-sales, and price-to-book ratios, which are displayed on the page when available. Comparing these ratios to industry peers and the company's historical averages provides context. Additionally, assessing growth prospects and profitability can offer a more complete picture. Always ensure the data is current, as valuation changes with market conditions.
Trading of DRTS outside regular market hours depends on whether it is eligible for pre-market or after-hours sessions, which typically run from 4:00 a.m. to 9:30 a.m. and 4:00 p.m. to 8:00 p.m. ET. Not all brokers support extended-hours trading, and liquidity may be lower, leading to wider spreads. Check with your brokerage and review the trading information on the page for specific availability.
Key financial metrics for DRTS include revenue growth, net income, earnings per share, operating margin, and return on equity. These indicators reveal profitability, efficiency, and financial health. Cash flow from operations and debt levels also matter for assessing sustainability. Investors can find these figures in quarterly and annual reports, and compare them over time to identify trends.
Investing in DRTS carries risks such as market volatility, industry-specific challenges, and company execution risks. Economic downturns, competitive pressures, and regulatory changes can negatively impact performance. Additionally, small-cap or sector-focused stocks may experience lower liquidity and higher price swings. Reviewing risk factors in SEC filings and staying informed about company developments helps investors understand potential downside scenarios.